Thomas Striepe - Sangui Biotech CEO and President and Executive Director

All Insiders . USA . 
Stock . Sangui Biotech International . Stakeholders . Insider . Thomas Striepe
SGBI Stock  USD 0.0002  0.00  0.00%   

CEO

Mr. Thomas Striepe is Chief Executive Officer, Director of Sangui Biotech International Inc. He is Vice President Accounting and Controlling at Treukonzept Finance GmbH, Hamburg, Germany, a financial services company. Prior to joining Treukonezpt Finance GmbH in 2004, he held management positions in the accounting departments of several German and international corporations. He holds an MBA of Hamburg University. since 2008.
Age 61
Tenure 17 years
Professional MarksMBA
Phone49 40 609 3120
Webhttps://www.sanguibiotech.com

Sangui Biotech Management Efficiency

The company has return on total asset (ROA) of (0.6411) % which means that it has lost $0.6411 on every $100 spent on assets. This is way below average. Sangui Biotech's management efficiency ratios could be used to measure how well Sangui Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Sangui Biotech International currently holds 48.9 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Sangui Biotech Inter has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Sangui Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Sangui Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sangui Biotech Inter sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sangui to invest in growth at high rates of return. When we think about Sangui Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 6 records

CEO Age

Brendan OGradyAssertio Therapeutics
N/A
Chintu RPhAmneal Pharmaceuticals, Class
52
Chirag PatelAmneal Pharmaceuticals, Class
58
Chintu PatelAmneal Pharmaceuticals, Class
49
Paul JosephsLifecore Biomedical
60
James HallLifecore Biomedical
62
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany. Sangui Biotech is traded on OTC Exchange in the United States. Sangui Biotech International [SGBI] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Asset-0.64

Sangui Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sangui Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-0.64
Profit Margin(1.27) %
Operating Margin(1.50) %
Current Valuation1.68 M
Shares Outstanding209.9 M
Shares Owned By Insiders13.03 %
Price To Earning(18.33) X
Price To Book46.44 X
Price To Sales10.09 X
Revenue69.19 K

Currently Active Assets on Macroaxis

CRMSalesforce
CCitigroup
GMGeneral Motors
WDWalker Dunlop
MSFTMicrosoft

Other Information on Investing in Sangui Pink Sheet

Sangui Biotech financial ratios help investors to determine whether Sangui Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sangui with respect to the benefits of owning Sangui Biotech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY